BioXcel Therapeutics, Inc. (BTAIQ)
0.052
+0.01
(+15.56%)
USD |
OTCM |
Oct 02, 16:00
BioXcel Therapeutics Profit Margin (Quarterly) : -8.08K% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.08K% |
| March 31, 2026 | -6.16K% |
| December 31, 2025 | -4.90K% |
| September 30, 2025 | -31.54K% |
| June 30, 2025 | -15.99K% |
| March 31, 2025 | -4.32K% |
| December 31, 2024 | -2.97K% |
| September 30, 2024 | -6.38K% |
| Date | Value |
|---|---|
| June 30, 2024 | -751.7% |
| March 31, 2024 | -4.60K% |
| December 31, 2023 | -5.92K% |
| September 30, 2023 | -14.81K% |
| June 30, 2023 | -11.71K% |
| March 31, 2023 | -25.63K% |
| December 31, 2022 | -23.03K% |
| September 30, 2022 | -30.51K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | -1.64% |
| Amgen, Inc. | 23.59% |
| BioCryst Pharmaceuticals, Inc. | 35.92% |
| Imunon, Inc. | -- |
| Curis, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -195.8% |
| Return on Invested Capital | -1.21K% |
| Gross Profit Margin (Quarterly) | 78.02% |
| Operating Margin (Quarterly) | -5.54K% |
| Return on Net Operating Assets | -1.34K% |